Unlocking Q1 Potential of McKesson (MCK): Exploring Wall Street Estimates for Key Metrics

Analysts on Wall Street project that McKesson (MCK) will announce quarterly earnings of $8.23 per share in its forthcoming report, representing an increase of 4.4% year over year. Revenues are projected to reach $96.08 billion, increasing 21.2% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.Bearing this in mind, let's now explore the average estimates of specific McKesson metrics that are commonly monitored and projected by Wall Street analysts.The average prediction of analysts places 'Revenue- U.S. Pharmaceutical' at $87.36 billion. The estimate suggests a change of +21.8% year over year.Analysts expect 'Revenue- Prescription Technology Solutions' to come in at $1.35 billion. The estimate indicates a change of +8.8% from the prior-year quarter.The combined assessment of analysts suggests that 'Revenue- International' will likely reach $3.67 billion. The estimate indicates a change of -0.7% from the prior-year quarter.Based on the collective assessment of analysts, 'Revenue- Medical-Surgical Solutions' should arrive at $2.70 billion. The estimate suggests a change of +2.6% year over year.Analysts predict that the 'Adjusted Operating Profit- U.S. Pharmaceutical' will reach $965.96 million. The estimate is in contrast to the year-ago figure of $815.00 million.It is projected by analysts that the 'Adjusted Operating Profit- International' will reach $100.22 million. Compared to the present estimate, the company reported $102.00 million in the same quarter last year.According to the collective judgment of analysts, 'Adjusted Operating Profit- Medical-Surgical Solutions' should come in at $215.97 million. Compared to the present estimate, the company reported $200.00 million in the same quarter last year.Analysts forecast 'Adjusted Operating Profit- Prescription Technology Solutions' to reach $249.95 million. Compared to the present estimate, the company reported $223.00 million in the same quarter last year. View all Key Company Metrics for McKesson here>>> Shares of McKesson have experienced a change of -3.6% in the past month compared to the +2.3% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), MCK is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks